ArticleClinical and translational science2026
Posaconazole Target Attainment in Critically Ill Children: A 15-Year Single-Center Retrospective Analysis.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posaconazole is a triazole antifungal agent used for prophylaxis and treatment of invasive fungal diseases. Posaconazole has high inter-individual variability in dose-exposure relationship and benefits from therapeutic drug monitoring (TDM). Adult studies report particularly high rates of subtherapeutic exposure among intensive care unit (ICU) patients related to changes in physiology during critical illness. The rates of subtherapeutic posaconazole exposure among critically ill children in ICU's are unknown. This single-center retrospective analysis at a large freestanding children's hospital used TDM results from 2010 to 2025 obtained while patients were undergoing care in a pediatric ICU. Therapeutic targets were ≥ 1.0 mg/L for treatment of infection and ≥ 0.7 mg/L for prophylaxis. A general linear mixed model (GLMM) was used to assess factors which differed between instances with therapeutic and subtherapeutic posaconazole concentrations. Sixty-two posaconazole concentrations from 30 ICU patients were analyzed, of which 24 (39%) concentrations were below target based on their therapeutic indication. Both univariate analysis and stepwise GLMM identified an association between liquid formulation and subtherapeutic targets (OR 29.6, CI 2.2-398.2, p = 0.01). However, even among critically ill children with IV posaconazole administration 13/46 (28%) measured concentrations remained subtherapeutic. Rates of subtherapeutic posaconazole exposure among critically ill children are high, though lower than reported from adult ICU cohorts. Liquid formulation use was associated with subtherapeutic concentrations, however appreciable instances of subtherapeutic exposure persist in patients receiving IV administration. Further research is needed to identify characteristics of critically ill patients at risk of subtherapeutic posaconazole exposure and to develop strategies to optimize attainment of appropriate medication exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.